Lexaria Bioscience Gelecekteki Büyüme
Future kriter kontrolleri 2/6
Lexaria Bioscience is forecast to grow earnings and revenue by 49.1% and 62.6% per annum respectively while EPS is expected to grow by 48.7% per annum.
Anahtar bilgiler
49.1%
Kazanç büyüme oranı
48.7%
EPS büyüme oranı
| Pharmaceuticals kazanç büyümesi | 23.7% |
| Gelir büyüme oranı | 62.6% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 23 Jul 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 8/31/2027 | 4 | -17 | N/A | N/A | 1 |
| 8/31/2026 | 1 | -9 | N/A | N/A | 2 |
| 8/31/2025 | 1 | -7 | N/A | -4 | 3 |
| 8/31/2024 | 0 | -5 | N/A | -3 | 3 |
| 5/31/2024 | 0 | -5 | -5 | -5 | N/A |
| 2/29/2024 | 0 | -5 | -5 | -5 | N/A |
| 11/30/2023 | 0 | -6 | -6 | -6 | N/A |
| 8/31/2023 | 0 | -7 | -6 | -6 | N/A |
| 5/31/2023 | 0 | -7 | -6 | -5 | N/A |
| 2/28/2023 | 0 | -7 | -5 | -5 | N/A |
| 11/30/2022 | 0 | -7 | -5 | -5 | N/A |
| 8/31/2022 | 0 | -7 | -5 | -5 | N/A |
| 5/31/2022 | 0 | -7 | -5 | -5 | N/A |
| 2/28/2022 | 0 | -7 | -5 | -5 | N/A |
| 11/30/2021 | 0 | -7 | -5 | -4 | N/A |
| 8/31/2021 | 1 | -6 | -4 | -4 | N/A |
| 5/31/2021 | 1 | -5 | -4 | -3 | N/A |
| 2/28/2021 | 1 | -4 | -3 | -3 | N/A |
| 11/30/2020 | 1 | -4 | -3 | -3 | N/A |
| 8/31/2020 | 0 | -4 | -3 | -3 | N/A |
| 5/31/2020 | 0 | -4 | -3 | -3 | N/A |
| 2/29/2020 | 0 | -4 | -3 | -3 | N/A |
| 11/30/2019 | 0 | -4 | -4 | -3 | N/A |
| 8/31/2019 | 0 | -4 | -4 | -3 | N/A |
| 5/31/2019 | 0 | -4 | -4 | -3 | N/A |
| 2/28/2019 | 0 | -6 | -3 | -3 | N/A |
| 11/30/2018 | 0 | -7 | -3 | -3 | N/A |
| 8/31/2018 | 0 | -7 | -3 | -3 | N/A |
| 5/31/2018 | 0 | -6 | -2 | -2 | N/A |
| 2/28/2018 | 0 | -3 | N/A | -2 | N/A |
| 11/30/2017 | 0 | -2 | N/A | -2 | N/A |
| 8/31/2017 | 0 | -2 | N/A | -2 | N/A |
| 5/31/2017 | 0 | -1 | N/A | -1 | N/A |
| 2/28/2017 | 0 | -1 | N/A | -1 | N/A |
| 11/30/2016 | 0 | -1 | N/A | -1 | N/A |
| 8/31/2016 | 0 | -1 | N/A | -1 | N/A |
| 5/31/2016 | 0 | -1 | N/A | -1 | N/A |
| 2/29/2016 | 0 | -2 | N/A | -1 | N/A |
| 11/30/2015 | 0 | -2 | N/A | -2 | N/A |
| 8/31/2015 | 0 | -2 | N/A | -2 | N/A |
| 5/31/2015 | 0 | -2 | N/A | -1 | N/A |
| 2/28/2015 | 0 | -2 | N/A | -1 | N/A |
| 11/30/2014 | N/A | -2 | N/A | -1 | N/A |
| 8/31/2014 | N/A | -2 | N/A | -1 | N/A |
| 7/31/2014 | 1 | -1 | N/A | 0 | N/A |
| 4/30/2014 | 1 | -1 | N/A | 0 | N/A |
| 1/31/2014 | 1 | 0 | N/A | 0 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: LEXX is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: LEXX is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: LEXX is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: LEXX's revenue (62.6% per year) is forecast to grow faster than the US market (8.9% per year).
Yüksek Büyüme Geliri: LEXX's revenue (62.6% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if LEXX's Return on Equity is forecast to be high in 3 years time